Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine

Back to Search
Print
Bookmark Trial

NCT00373958

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Fayetteville, Arkansas, 72703, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Vaccines, Pneumococcal
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
42-98 days
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy 2-month-old infants.

- Available for the entire study period.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Previous vaccination with any vaccine before the start of the study.


- Known contraindication to vaccination.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Vaccines, PneumococcalStudy to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
NCT00368966
  1. Ferrol, A Coruna
  2. Santiago de Compostela, A Coruna
  3. Argentona, Barcelona
  4. Sabadell, Barcelona
  5. Sant Adria de Besos, Barcelona
  6. Sant Cugat del Valles, Barcelona
  7. Sant Cugat del Valles, Barcelona
  8. Bilbao, Bizkaia
  9. Burela, Lugo
  10. Alcorcon, Madrid
  11. Fuenlabrada, Madrid
  12. Getafe, Madrid
  13. Getafe, Madrid
  14. Mostoles, Madrid
  15. Parla, Madrid
  16. Antequera, Malaga
  17. Pamplona, Navarra
  18. Vigo, Pontevedra
  19. Burjassot, Valencia
  20. La Eliana, Valencia
  21. Quart de Poblet, Valencia
  22. A Coruna,
  23. Almeria,
  24. Almeria,
  25. Almeria,
  26. Barcelona,
  27. Barcelona,
  28. La Coruna,
  29. Madrid,
  30. Madrid,
  31. Malaga,
  32. Ourense,
  33. Sevilla,
  34. Valencia,
  35. Valencia,
  36. Valencia,
  37. Valencia,
  38. Valencia,
  39. Valencia,
  40. Valencia,
  41. Valencia,
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Vaccines, PneumococcalStudy Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine
NCT00373958
  1. Fayetteville, Arkansas
  2. Jonesboro, Arkansas
  3. Little Rock, Arkansas
  4. Downey, California
  5. Fontana, California
  6. Loma Linda, California
  7. Paramount, California
  8. Riverside, California
  9. Centennial, Colorado
  10. Norwich, Connecticut
  11. Tampa, Florida
  12. Marietta, Georgia
  13. Woodstock, Georgia
  14. Chicago, Illinois
  15. Park Ridge, Illinois
  16. Overland Park, Kansas
  17. Bardstown, Kentucky
  18. Louisville, Kentucky
  19. Louisville, Kentucky
  20. Bronx, New York
  21. Rochester, New York
  22. Cincinnati, Ohio
  23. Cleveland, Ohio
  24. Mason, Ohio
  25. Latrobe, Pennsylvania
  26. Pittsburgh, Pennsylvania
  27. Pittsburgh, Pennsylvania
  28. Pittsburg, Pennsylvania
  29. Sellersville, Pennsylvania
  30. Wexford, Pennsylvania
  31. Charleston, South Carolina
  32. Jackson, Tennessee
  33. The Woodlands, Texas
  34. Murray, Utah
  35. Provo, Utah
  36. Richmond, Virginia
  37. Vienna, Virginia
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Vaccines, PneumococcalStudy to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
NCT00366340
  1. Bad Kreuznach,
  2. Bad Saulgau,
  3. Bad Sobernheim,
  4. Berlin,
  5. Berlin,
  6. Berlin,
  7. Berlin,
  8. Berlin,
  9. Berlin,
  10. Birkenfeld,
  11. Bobingen,
  12. Bramsche,
  13. Bretten,
  14. Cham,
  15. Ehingen,
  16. Erlangen,
  17. Eschwege,
  18. Flensburg,
  19. Gau-Odernheim,
  20. Hamburg,
  21. Herzogenaurach,
  22. Hoechberg,
  23. Kehl,
  24. Kiel,
  25. Kleve,
  26. Krefeld,
  27. Ludwigshafen,
  28. Luebeck,
  29. Mainz,
  30. Metzingen,
  31. Minden,
  32. Muenster,
  33. Muenster,
  34. Neumuenster,
  35. Neumünster,
  36. Neustadt/Aisch,
  37. Niebuell,
  38. Nuernberg,
  39. Nuernberg,
  40. Oberkirch,
  41. Olching,
  42. Pforzheim,
  43. Porta Westfalica,
  44. Ravensburg,
  45. Tettnang,
  46. Vellmar,
  47. Weiden,
  48. Weilheim,
  49. Welzheim,
  50. Wiesbaden,
  51. Zirndorf,
ALL GENDERS
56 Days+
years
MULTIPLE SITES
Vaccines, PneumococcalStudy to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
NCT00366678
  1. Albi,
  2. Amiens,
  3. Ancenis,
  4. Blanquefort,
  5. Bondues,
  6. Bordeaux,
  7. Brest,
  8. Chalons en champagne,
  9. Creteil,
  10. Dijon,
  11. Draguignan,
  12. Ecully,
  13. Essey-les-nancy,
  14. Floirac,
  15. Frejus,
  16. Garges-les-Gonesse,
  17. Illkirch,
  18. Joue les tours,
  19. Le havre,
  20. Le plessis-trevise,
  21. Le pontet,
  22. Les lilas,
  23. Les sables d'olonne,
  24. Libourne,
  25. Lingolsheim,
  26. Lyon,
  27. Lyon,
  28. Marcq en baroeul,
  29. Maromme,
  30. Moutiers,
  31. Nancy,
  32. Nice,
  33. Nogent sur marne,
  34. Nogent-sur-marne,
  35. Oullins,
  36. Paris,
  37. Rouen,
  38. Strasbourg,
  39. Strasbourg,
  40. Thionville,
  41. Tours,
  42. Tresses melac,
  43. Vandoeuvre les nancy,
  44. Vaulx-en-velin,
  45. Villeneuve d'ascq,
  46. Vitry-sur-seine,
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine
Official Title  ICMJE A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States
Brief Summary The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal vaccine (13vPnC) compare to the 7-valent pneumococcal vaccine (7vPnC) and to compare the immune response to concomitant vaccines administered with 13vPnC and 7vPnC.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Condition  ICMJE Vaccines, Pneumococcal
Intervention  ICMJE
  • Biological: 13 valent pneumococcal conjugate vaccine
    1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
  • Biological: 7vPnc pneumococcal conjugate vaccine
    1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
Study Arms  ICMJE
  • Experimental: 13vPnC vaccine
    Intervention: Biological: 13 valent pneumococcal conjugate vaccine
  • Active Comparator: 7vPnC vaccine
    Intervention: Biological: 7vPnc pneumococcal conjugate vaccine
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 17, 2013)		666
Original Enrollment  ICMJE
 (submitted: September 7, 2006)		640
Actual Study Completion Date  ICMJE June 2008
Actual Primary Completion Date June 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Healthy 2-month-old infants.
  • Available for the entire study period.

Exclusion criteria:

  • Previous vaccination with any vaccine before the start of the study.
  • Known contraindication to vaccination.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 42 Days to 98 Days   (Child)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00373958
Other Study ID Numbers  ICMJE 6096A1-004
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Pfizer
Verification Date January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP